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Background
Diabetes mellitus is one of the most prevalent chronic diseases 
in children and adolescents; about 151,000 people below the age of 
20 have diabetes [1]. Poorly controlled diabetes mellitus predisposes 
children and adolescents to acute and chronic complications. Adults 
with diabetes have a ten-fold increase in the risk of cardiovascular 
disease as compared to the general population [2]. These complications 
place a heavy burden on the national healthcare budget.
Diabetes mellitus is classified into four major types: type 1, type 2, 
gestational, and other specific types, for example, cystic fibrosis-related 
diabetes. Type 1 diabetes (T1D) is caused by autoimmune destruction 
of the beta cells of the pancreas leading to insulinopenia [3]. Type 2 
diabetes (T2D) results from a combination of Insulin Resistance (IR) 
and beta cell insulin secretory insufficiency. The rising incidence of 
obesity has made it more difficult to differentiate between these types 
of diabetes in children. There is a new variant of diabetes in children 
designated as double diabetes, or hybrid diabetes, in which both T1D 
(antibody positivity) and T2D (insulin resistance and insufficiency) co-
exist in the same individual (Figure 1).
Childhood obesity is one of the most serious public health challenges 
of the 21st century [4]. According to the National Health and Nutrition 
Examination Survey data, about 16% of children and adolescents in 
the United States are obese with a Body Mass Index (BMI) (kg/m2) ≥ 
95th percentile for age and gender [5-8] with the highest percentages in 
teens. The prevalence of obesity has tripled in the past three decades [9] 
among male and female adolescents, and across many racial and ethnic 
groups [10,11]. Although obesity is associated primarily with T2D due 
to IR [12], it may also impact T1D morbidity and phenotype by causing 
earlier exhaustion of the beta cells through IR.  
A new subset of diabetes mellitus, known as double diabetes, is 
becoming increasingly prevalent as a result of the epidemic of childhood 
obesity [13-15]. In double diabetes, elements of both T1D and T2D 
co-exist. In this condition, individuals with T1D have insensitivity 
to insulin that is most often associated with obesity; and individuals 
thought to have T2D have diabetes-associated autoantibodies against 
the pancreatic beta cells [12]. The prevalence of double diabetes is 
unknown [13] however, about 25% of children with T1D are either 
overweight or obese [16].   Conversely, about 35% of children and 
adolescents with T2D have at least one diabetes-associated antibody 
[17].  
The availability of insulin analogs and insulin delivery devices has 
improved diabetes management in the US. However, according to 
recent studies, the prevalence of poorly-controlled diabetes in youth 
is still high [1]. A report by the SEARCH for Diabetes in Youth Study 
group showed that a high proportion of youth with diabetes had 
elevated HbA1c levels, with 17% of the youth with TIDM, and 27% 
of those with T2D showing poor control, defined as HbA1c ≥ 9.5%. 
The physiological factors that contribute to poor glycemic control in 
youth are in part related to the hormonal changes in puberty, which 
may lead to weight gain. Puberty is associated with relative IR, as 
reflected in a two to threefold increase in the peak insulin response to 
oral or intravenous glucose [18], as well as an insulin-mediated glucose 
disposal that is approximately 30% lower in adolescents than in pre-
pubertal children or young adults [19]. Evidence for the coexistence 
of IR and insulin deficiency in childhood-onset T1D adults has also 
been demonstrated by the insulin-glucose clamp technique [20,21]. 
The increasing IR, obesity, and deterioration of glycemic control in 
adolescents create a great need for alternative therapeutic strategies in 
adolescents with double diabetes. 
Lack of Consensus on Therapeutic Modalities for 
Double Diabetes 
There is no consensus for the best therapeutic regimen for children 
and adolescents with double diabetes. However, because IR is central to 
its pathophysiological mechanism, optimal management necessitates 
the addition of insulin sensitizers under appropriate clinical 
circumstances to the patient’s therapeutic regimen [15]. Intensification 
of lifestyle modification strategies should be encouraged to maintain 
normal weight and attenuate IR. Finally, because these patients require 
increased doses of insulin to maintain euglycemia, it is necessary to 
develop an insulin titration regimen that would ensure adequate 
glycemic control.
The Need for Adjunctive Metformin Regimen for 
Double Diabetes 
In general, patients with double diabetes are overweight or obese 
and the resultant IR increases their exogenous insulin requirement 
[4]. However, unlike T1D and T2D, there is no consensus for the 
TID=type 1 diabetes, T2D=type 2 diabetes, FBG=fasting blood glucose, 
2HPP=2 hour post prandial glucose level; BMI=body mass index; 
Abs=antibodies
Figure 1: The Relationship between type 1, type 2, and double diabetes.
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best therapeutic regimen for children and adolescents with double 
diabetes. One such strategy is the addition of a drug that increases 
insulin sensitivity such as metformin, a biguanide that acts principally 
in the liver by inhibiting hepatic gluconeogenesis and thereby reducing 
hepatic glucose production [22]. Metformin is approved by the Food 
and Drug Administration for use in children with T2D, and recently it 
has been recommended that metformin added to insulin therapy might 
be used in clinical practice in adolescents with T1D who are poorly 
controlled and show evidence of IR (double diabetes) as noted in T2D 
[23].
Given the rising prevalence of obesity in the general population 
we speculate that many children with T1D will eventually also become 
insulin resistant.  The coexistence of both T1D and T2D in an individual 
should in principle denote an increased risk for the complications of 
both conditions [24] . Therefore, it is possible that these individuals are 
at higher risk for both the microvascular and metabolic complications 
of T1D and the macrovascular complications of T2D [15]. Such 
a double-hit effect will result in poorer health outcomes, and put 
increased pressure on the national healthcare budget. Thus, it is timely 
to devise an appropriate management protocol to improve glycemic 
control in this burgeoning sub-population.
Because of the paucity of data on the role of adjunctive metformin 
therapy in children and adolescents with double diabetes, our group at 
the University of Massachusetts is conducting a randomized, double-
blind, placebo-controlled trial to evaluate the effect of adjunctive 
metformin therapy in children and adolescents with double diabetes. 
The Need for an Insulin Titration Regimen for Double 
Diabetes 
Another therapeutic modality for individuals with double diabetes 
is the exploration of optimal insulin titration regimen to ensure 
euglycemia. Patients with double diabetes are overweight or obese and 
the resultant IR increases their insulin requirement [4]. However, in 
addition to requiring a high insulin dose, evidence suggests that many 
patients often do not have the insulin doses titrated sufficiently to 
achieve target levels of glucose control [25,26]. These patients remain 
on suboptimal doses of insulin and fail to reach treatment targets 
[27]. In a recent study Blonde et al. [27] demonstrated the efficacy of 
algorithm-guided, patient titration of once daily long acting insulin 
in normalizing HbA1c in adult patients with T2D. Our group is also 
conducting a randomized control trial to explore the role of protocol-
driven treat-to-target regimen in children and adolescents with double 
diabetes. Specifically, we will investigate whether a titrated insulin 
regimen alone would have a superior-or similar effect to combined 
metformin and titrated insulin regimen in children and adolescents 
with double diabetes and how this combination of treatment compares 
to standard insulin therapy.
In conclusion, the global pandemic of obesity in children and 
adolescents has resulted in a new expression of diabetes mellitus 
designated as double diabetes. The entity encompasses the autoimmune 
load of T1D and the metabolic load of T2D. There is no consensus 
on the best therapeutic modality for this new expression of diabetes 
mellitus. Optimal therapeutic options must address the coexistence of 
both metabolic and autoimmune components of diabetes mellitus in 
the patient. There have also been calls to revise the current classification 
of diabetes mellitus to take into account the surging prevalence of 
double diabetes in children and adolescents.
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